Cerus Corporation (NASDAQ:CERS) Short Interest Update

Key Points

• Short interest in Cerus Corporation has declined significantly, dropping by 29.2% to 6,900,000 shares as of August 31, indicating a decreasing bearish sentiment towards the stock.
• Cerus reported a $60.1 million in revenue for the last quarter, surpassing analyst expectations of $51.8 million, despite EPS of ($0.03) that missed the consensus estimate.
• Institutional investors currently own 78.37% of Cerus shares, with notable increases in holdings from companies like Wasatch Advisors and Millennium Management.

Cerus Corporation (NASDAQ:CERS - Get Free Report) was the target of a significant drop in short interest in August. As of August 31st, there was short interest totaling 6,900,000 shares, a drop of 29.2% from the August 15th total of 9,740,000 shares. Approximately 3.8% of the shares of the stock are sold short. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 6.3 days. Based on an average trading volume of 1,100,000 shares, the short-interest ratio is currently 6.3 days. Approximately 3.8% of the shares of the stock are sold short.

Cerus Price Performance

NASDAQ:CERS traded up $0.16 during trading hours on Friday, reaching $1.46. 6,017,899 shares of the company's stock were exchanged, compared to its average volume of 1,079,960. The company has a market capitalization of $279.88 million, a P/E ratio of -14.60 and a beta of 1.63. Cerus has a 12 month low of $1.12 and a 12 month high of $2.24. The company has a quick ratio of 1.35, a current ratio of 2.00 and a debt-to-equity ratio of 1.01. The business's 50-day simple moving average is $1.30 and its two-hundred day simple moving average is $1.35.

Cerus (NASDAQ:CERS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($0.03) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $60.10 million during the quarter, compared to analyst estimates of $51.80 million. Cerus had a negative return on equity of 33.77% and a negative net margin of 9.81%. Cerus has set its FY 2025 guidance at EPS. Sell-side analysts expect that Cerus will post -0.08 EPS for the current fiscal year.

Institutional Trading of Cerus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northern Trust Corp grew its stake in shares of Cerus by 1.2% during the fourth quarter. Northern Trust Corp now owns 1,634,780 shares of the biotechnology company's stock valued at $2,518,000 after purchasing an additional 18,878 shares during the last quarter. Jane Street Group LLC grew its stake in shares of Cerus by 37.6% during the fourth quarter. Jane Street Group LLC now owns 409,408 shares of the biotechnology company's stock valued at $630,000 after purchasing an additional 111,858 shares during the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Cerus during the fourth quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its stake in shares of Cerus by 13.5% during the fourth quarter. BNP Paribas Financial Markets now owns 206,472 shares of the biotechnology company's stock valued at $318,000 after purchasing an additional 24,575 shares during the last quarter. Finally, Deutsche Bank AG grew its stake in shares of Cerus by 70.9% during the fourth quarter. Deutsche Bank AG now owns 161,381 shares of the biotechnology company's stock valued at $249,000 after purchasing an additional 66,961 shares during the last quarter. Institutional investors own 78.37% of the company's stock.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.